早期治疗反应可预测银屑病关节炎患者6个月和1年的疾病活动度结局
基于GO-REVEAL随机对照试验中216例接受戈利木单抗治疗的患者数据,采用3个月和6个月疾病活动度作为诊断测试预测治疗结局。3个月DAPSA对6个月疾病活动度判别优秀(AUC 0.92),3个月未达至少中度活动度者6个月达LDA概率<22%,3个月达DAPSA 85%反应者6个月LDA或缓解概率84%,结果在英夫利西单抗IMPACT 2队列中验证。
要点
- 3个月DAPSA是6个月疾病活动度的优秀判别指标,AUC为0.92。
- 3个月未达至少中度活动度者,6个月达LDA的估计概率<22%。
- 3个月达DAPSA 85%反应者,6个月达LDA或缓解的概率为84%。
核心结论
- 在银屑病关节炎中实施治疗3个月后即可评估达成治疗目标的潜力,这支持将3个月评估作为治疗调整的必要节点。
研究设计与样本
- 基于纳入戈利木单抗随机对照试验GO-REVEAL的216例患者数据,采用3个月和6个月疾病活动度作为诊断测试进行诊断测试分析。
- 通过回归分析估计达到至少LDA的概率,疾病活动度采用DAPSA测量,结果在英夫利西单抗IMPACT 2独立试验队列中验证。
主要发现
- 3个月DAPSA水平对6个月疾病活动度为优秀测试,AUC为0.92,对1年疾病活动度AUC为0.88。
- 若患者接受戈利木单抗3个月后未达到至少中度疾病活动度,6个月达LDA的估计概率可量化为<22%。
- 3个月达DAPSA 85%的患者6个月达LDA或缓解的概率为84%。
- 所有结果在英夫利西单抗IMPACT 2独立试验队列中得到验证。
关键数值与推荐
- 3个月DAPSA预测6个月疾病活动度的AUC为0.92,预测1年疾病活动度的AUC为0.88。
- 3个月未达至少中度疾病活动度者6个月达LDA的估计概率<22%。
- 3个月达DAPSA 85%者6个月达LDA或缓解的概率为84%。
临床怎么用
- 原文结论认为,在银屑病关节炎治疗3个月后即可评估达成治疗目标的潜力,支持将3个月评估作为治疗调整的必要节点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In PsA management, remission and low disease activity represent preferential treatment targets. We aimed at evaluating the predictive value and clinical use of initial therapeutic response for subsequent achievement of these targets. METHODS: Based on data of 216 patients enrolled in a randomized controlled trial of golimumab (GO-REVEAL), we performed diagnostic testing analyses using 3- and 6-month disease activity as tests for treatment outcomes to understand the implications of early response. In regression analyses, we estimated the probabilities for achieving at least LDA. Disease activity was measured by the disease activity index for PsA (DAPSA). RESULTS: Three-month DAPSA levels were excellent tests for disease activity at 6 months (and at 1 year), with areas under the receiver operating characteristic curves of 0.92 (and 0.88, respectively). The estimated probability for 6-month LDA could be quantified as <22% if patients did not reach at least moderate disease activity after 3 months on golimumab. Similar data were seen for early DAPSA response: patients achieving a DAPSA 85% at 3 months had an 84% probability for 6-month LDA or REM. All results were validated in an independent trial cohort of patients treated with infliximab (IMPACT 2). CONCLUSION: Three months after implementation of therapy in PsA, it is already possible to evaluate the potential for accomplishing therapeutic goals. This substantiates the choice of the 3-month assessment as essential for treatment adaptations.
引用
- Schoels MM, Landesmann U, Alasti F, et al. Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. Rheumatology (Oxford). 2018. PMID: 29481661. doi:10.1093/rheumatology/key004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。